Athel Al Unloaded 14,934 Shares of Trecora Resources (TREC); Last Week ANI Pharmaceuticals, Inc. (ANIP) Analysts

Among 6 analysts covering ANI Pharma (NASDAQ:ANIP), 3 have Buy rating, 0 Sell and 3 Hold. Therefore 50% are positive. ANI Pharma had 19 analyst reports since July 31, 2015 according to SRatingsIntel. Raymond James initiated the shares of ANIP in report on Thursday, June 23 with “Strong Buy” rating. The stock of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) earned “Buy” rating by TH Capital on Monday, September 28. The rating was maintained by Canaccord Genuity on Monday, October 16 with “Buy”. The firm earned “Neutral” rating on Wednesday, February 22 by TH Capital. As per Tuesday, July 19, the company rating was upgraded by Oppenheimer. The firm earned “Buy” rating on Thursday, December 7 by Canaccord Genuity. The rating was maintained by Oppenheimer on Friday, August 5 with “Outperform”. TH Capital maintained the stock with “Neutral” rating in Tuesday, August 4 report. The firm earned “Buy” rating on Wednesday, August 9 by Canaccord Genuity. The firm has “Buy” rating given on Wednesday, September 2 by TheStreet. See ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) latest ratings:

07/12/2017 Broker: Canaccord Genuity Rating: Buy New Target: $75.0 Maintain
02/11/2017 Broker: Roth Capital Rating: Hold New Target: $64.0 Maintain
16/10/2017 Broker: Canaccord Genuity Rating: Buy Maintain

Trecora Resources major shareholder and an insider Athel Al not a long ago made a sale of 14,934 company shares with a total value of $184,435 at the avg market share price of $12.4. He also sold 138,989 shares valued at $1,765,606 USD in the last month. Athel Al presently holds 3.07 million shares or 12.64% of Trecora Resources’s market cap.

The stock decreased 0.84% or $0.5 during the last trading session, reaching $59.22. About 56,797 shares traded. ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) has declined 0.02% since February 20, 2017 and is downtrending. It has underperformed by 16.72% the S&P500.

ANI Pharmaceuticals, Inc., a specialty pharmaceutical company, develops, makes, and markets branded and generic prescription pharmaceuticals in the United States. The company has market cap of $689.50 million. It focuses on producing controlled substances, anti-cancer , hormones and steroids, and complex formulations. It has a 92.24 P/E ratio. The firm offers Erythromycin Ethylsuccinate to treat infections; Esterified Estrogen with Methyltestosterone for treating vasomotor symptoms of menopause; Etodolac to treat pain caused by osteoarthritis, rheumatoid arthritis, and other conditions; Fenofibrate for treating hypercholesterolemia; Flecainide to treat arrhythmia; Fluvoxamine for treating obsessive-compulsive and social anxiety disorders; and Hydrocortisone Enema and Cortenema to treat ulcerative colitis.

Investors sentiment increased to 1.69 in Q3 2017. Its up 0.63, from 1.06 in 2017Q2. It improved, as 16 investors sold ANI Pharmaceuticals, Inc. shares while 26 reduced holdings. 22 funds opened positions while 49 raised stakes. 6.31 million shares or 1.29% less from 6.39 million shares in 2017Q2 were reported. 7,050 are held by Diker Management Ltd Liability Com. Guggenheim Ltd Llc accumulated 0.01% or 52,366 shares. First Manhattan accumulated 0.11% or 373,595 shares. Riverhead Cap Ltd holds 1,083 shares. Voya Invest Management Limited Liability Corporation accumulated 4,192 shares or 0% of the stock. Bank & Trust Of New York Mellon Corporation has 0% invested in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) for 156,865 shares. State Of Alaska Department Of Revenue reported 1,779 shares. Parametric Associates Limited Liability stated it has 15,768 shares. 29,722 are owned by Jw Asset Mgmt. Highland Cap Management Lp has 0.01% invested in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP). Meeder Asset Management has 0% invested in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) for 27 shares. Dana Inv Advisors accumulated 44,505 shares. Architects has invested 0.01% in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP). American Interest accumulated 6,467 shares. Tiaa Cref Mgmt Limited Liability has 0% invested in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) for 40,285 shares.

Analysts await Trecora Resources (NYSE:TREC) to report earnings on March, 7. They expect $0.09 EPS, up 28.57% or $0.02 from last year’s $0.07 per share. TREC’s profit will be $2.19M for 33.89 P/E if the $0.09 EPS becomes a reality. After $0.07 actual EPS reported by Trecora Resources for the previous quarter, Wall Street now forecasts 28.57% EPS growth.

Trecora Resources primarily manufactures and sells various specialty hydrocarbons and synthetic waxes in the United States. The company has market cap of $296.53 million. The firm operates two divisions, Petrochemical and Specialty Waxes. It has a 93.13 P/E ratio. The Petrochemical segment offers hydrocarbons and other petroleum based products, such as isopentane, normal pentane, isohexane, and hexane used in the production of polyethylene, packaging, polypropylene, expandable polystyrene, poly-iso/urethane foams, and crude oil from the Canadian tar sands, as well as in the catalyst support industry.

Free Email Newsletter

Enter your email address below to get the latest news and analysts’ ratings for your stocks with our free daily email newsletter: